| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Colitis, Ulcerative | 46 | 2025 | 801 | 6.910 |
Why?
|
| Crohn Disease | 29 | 2025 | 806 | 5.210 |
Why?
|
| Inflammatory Bowel Diseases | 31 | 2025 | 647 | 4.380 |
Why?
|
| Colon | 15 | 2023 | 541 | 2.200 |
Why?
|
| MicroRNAs | 8 | 2020 | 591 | 1.820 |
Why?
|
| Colitis | 9 | 2021 | 262 | 1.640 |
Why?
|
| Colonic Neoplasms | 8 | 2020 | 589 | 1.370 |
Why?
|
| Inflammation | 7 | 2023 | 1063 | 1.070 |
Why?
|
| Cholangitis, Sclerosing | 5 | 2023 | 54 | 1.040 |
Why?
|
| Ustekinumab | 3 | 2025 | 52 | 0.970 |
Why?
|
| Colectomy | 6 | 2023 | 192 | 0.970 |
Why?
|
| Vitamin D Deficiency | 3 | 2021 | 107 | 0.950 |
Why?
|
| Colorectal Neoplasms | 6 | 2023 | 1069 | 0.930 |
Why?
|
| Vitamin D | 4 | 2021 | 273 | 0.900 |
Why?
|
| Leukocyte L1 Antigen Complex | 6 | 2024 | 51 | 0.870 |
Why?
|
| Retrospective Studies | 33 | 2025 | 10287 | 0.850 |
Why?
|
| Hospitalization | 6 | 2019 | 943 | 0.840 |
Why?
|
| Humans | 90 | 2025 | 96105 | 0.830 |
Why?
|
| Renin-Angiotensin System | 4 | 2019 | 84 | 0.830 |
Why?
|
| Ileum | 4 | 2023 | 169 | 0.820 |
Why?
|
| Gastrointestinal Agents | 7 | 2025 | 183 | 0.820 |
Why?
|
| Middle Aged | 41 | 2025 | 28368 | 0.790 |
Why?
|
| Adult | 45 | 2025 | 28721 | 0.780 |
Why?
|
| Cyclosporine | 3 | 2019 | 242 | 0.770 |
Why?
|
| Aspirin | 2 | 2021 | 169 | 0.770 |
Why?
|
| Immunosuppressive Agents | 5 | 2020 | 995 | 0.770 |
Why?
|
| Clostridium Infections | 3 | 2020 | 128 | 0.760 |
Why?
|
| Proctocolectomy, Restorative | 5 | 2025 | 115 | 0.730 |
Why?
|
| Remission Induction | 10 | 2025 | 769 | 0.730 |
Why?
|
| Antirheumatic Agents | 1 | 2022 | 61 | 0.710 |
Why?
|
| Fecal Microbiota Transplantation | 2 | 2020 | 80 | 0.710 |
Why?
|
| Fatigue | 1 | 2022 | 185 | 0.700 |
Why?
|
| Colonic Pouches | 4 | 2025 | 97 | 0.700 |
Why?
|
| Ileal Diseases | 2 | 2019 | 25 | 0.700 |
Why?
|
| Colonoscopy | 8 | 2023 | 304 | 0.690 |
Why?
|
| Postoperative Complications | 7 | 2025 | 2591 | 0.690 |
Why?
|
| Male | 49 | 2025 | 45863 | 0.680 |
Why?
|
| Pouchitis | 4 | 2025 | 57 | 0.660 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2022 | 187 | 0.650 |
Why?
|
| Pyoderma Gangrenosum | 1 | 2020 | 20 | 0.640 |
Why?
|
| Surgical Stomas | 1 | 2020 | 22 | 0.640 |
Why?
|
| Intestinal Mucosa | 7 | 2019 | 825 | 0.640 |
Why?
|
| Ulcer | 2 | 2022 | 38 | 0.640 |
Why?
|
| Female | 48 | 2025 | 50028 | 0.630 |
Why?
|
| Antibodies, Monoclonal, Humanized | 7 | 2025 | 1021 | 0.630 |
Why?
|
| Severity of Illness Index | 10 | 2025 | 1979 | 0.590 |
Why?
|
| Piperidines | 7 | 2022 | 171 | 0.590 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2019 | 42 | 0.580 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2019 | 98 | 0.570 |
Why?
|
| Patient Admission | 1 | 2019 | 122 | 0.570 |
Why?
|
| Kynurenine | 1 | 2018 | 23 | 0.560 |
Why?
|
| Young Adult | 18 | 2025 | 7025 | 0.560 |
Why?
|
| Gene Expression Profiling | 3 | 2019 | 1535 | 0.550 |
Why?
|
| Tryptophan | 1 | 2018 | 105 | 0.550 |
Why?
|
| Thrombospondins | 1 | 2017 | 15 | 0.540 |
Why?
|
| Caveolin 1 | 1 | 2017 | 25 | 0.530 |
Why?
|
| Dysbiosis | 1 | 2018 | 91 | 0.530 |
Why?
|
| Receptors, Interleukin | 1 | 2017 | 39 | 0.520 |
Why?
|
| Collagen Type I | 1 | 2017 | 74 | 0.520 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2019 | 294 | 0.520 |
Why?
|
| Treatment Outcome | 20 | 2025 | 9175 | 0.520 |
Why?
|
| Focal Adhesions | 1 | 2017 | 66 | 0.510 |
Why?
|
| Recurrence | 7 | 2023 | 1218 | 0.510 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 3 | 2025 | 44 | 0.500 |
Why?
|
| DNA Methylation | 3 | 2020 | 703 | 0.490 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2021 | 1346 | 0.480 |
Why?
|
| Pyrimidines | 5 | 2022 | 386 | 0.470 |
Why?
|
| Duodenal Diseases | 1 | 2015 | 25 | 0.460 |
Why?
|
| Seasons | 1 | 2016 | 246 | 0.450 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 1 | 2014 | 21 | 0.450 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2014 | 56 | 0.440 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 94 | 0.440 |
Why?
|
| Hematoma | 1 | 2015 | 109 | 0.440 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2014 | 204 | 0.430 |
Why?
|
| Case-Control Studies | 6 | 2021 | 1957 | 0.430 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2014 | 7 | 0.420 |
Why?
|
| ras Proteins | 1 | 2014 | 134 | 0.410 |
Why?
|
| Acute Kidney Injury | 1 | 2018 | 340 | 0.410 |
Why?
|
| Maintenance Chemotherapy | 3 | 2025 | 91 | 0.410 |
Why?
|
| Intestine, Small | 1 | 2015 | 310 | 0.400 |
Why?
|
| Patient Readmission | 1 | 2017 | 413 | 0.400 |
Why?
|
| Aged | 15 | 2021 | 20968 | 0.390 |
Why?
|
| Adolescent | 12 | 2025 | 9895 | 0.380 |
Why?
|
| Janus Kinase Inhibitors | 2 | 2025 | 29 | 0.360 |
Why?
|
| Pyrroles | 4 | 2020 | 172 | 0.350 |
Why?
|
| Proto-Oncogenes | 1 | 2011 | 61 | 0.340 |
Why?
|
| Receptors, Calcitriol | 4 | 2019 | 131 | 0.340 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2014 | 684 | 0.340 |
Why?
|
| Infliximab | 4 | 2020 | 163 | 0.330 |
Why?
|
| Prospective Studies | 11 | 2025 | 4671 | 0.330 |
Why?
|
| C-Reactive Protein | 3 | 2023 | 206 | 0.320 |
Why?
|
| Endoscopy, Gastrointestinal | 3 | 2023 | 161 | 0.320 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 750 | 0.320 |
Why?
|
| Risk Factors | 10 | 2020 | 5961 | 0.310 |
Why?
|
| Phenotype | 6 | 2025 | 2578 | 0.310 |
Why?
|
| Tertiary Care Centers | 3 | 2025 | 128 | 0.290 |
Why?
|
| Follow-Up Studies | 7 | 2025 | 3927 | 0.290 |
Why?
|
| Feces | 3 | 2021 | 360 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2020 | 713 | 0.290 |
Why?
|
| Logistic Models | 5 | 2018 | 1268 | 0.290 |
Why?
|
| Adenocarcinoma | 2 | 2019 | 1215 | 0.290 |
Why?
|
| Transcriptome | 2 | 2018 | 769 | 0.280 |
Why?
|
| Secondary Prevention | 2 | 2019 | 179 | 0.270 |
Why?
|
| Real-Time Polymerase Chain Reaction | 3 | 2014 | 299 | 0.270 |
Why?
|
| Carcinogenesis | 3 | 2019 | 235 | 0.270 |
Why?
|
| RNA, Long Noncoding | 2 | 2019 | 130 | 0.260 |
Why?
|
| Antibodies, Monoclonal | 4 | 2020 | 1429 | 0.260 |
Why?
|
| Signal Transduction | 8 | 2019 | 3581 | 0.260 |
Why?
|
| Lymphocyte Activation | 2 | 2021 | 810 | 0.260 |
Why?
|
| Cryoglobulinemia | 1 | 2006 | 5 | 0.250 |
Why?
|
| Hepatitis C, Chronic | 1 | 2007 | 96 | 0.250 |
Why?
|
| Chronic Disease | 3 | 2022 | 983 | 0.250 |
Why?
|
| Epigenesis, Genetic | 2 | 2021 | 555 | 0.250 |
Why?
|
| Fatty Liver | 1 | 2007 | 108 | 0.240 |
Why?
|
| Disease Progression | 5 | 2019 | 1562 | 0.240 |
Why?
|
| Angiotensin II | 4 | 2019 | 95 | 0.240 |
Why?
|
| Liver Cirrhosis | 1 | 2007 | 276 | 0.230 |
Why?
|
| Down-Regulation | 4 | 2020 | 526 | 0.220 |
Why?
|
| Prognosis | 4 | 2025 | 4028 | 0.210 |
Why?
|
| Luminescent Measurements | 1 | 2024 | 64 | 0.210 |
Why?
|
| Hepatitis C | 1 | 2006 | 185 | 0.210 |
Why?
|
| Registries | 3 | 2020 | 986 | 0.210 |
Why?
|
| Biological Products | 3 | 2021 | 179 | 0.210 |
Why?
|
| Oxadiazoles | 1 | 2023 | 39 | 0.200 |
Why?
|
| Indans | 1 | 2023 | 37 | 0.200 |
Why?
|
| Biosensing Techniques | 1 | 2024 | 81 | 0.200 |
Why?
|
| Calcineurin Inhibitors | 2 | 2021 | 53 | 0.200 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2007 | 426 | 0.200 |
Why?
|
| Time Factors | 4 | 2019 | 5580 | 0.190 |
Why?
|
| Mice | 12 | 2022 | 12537 | 0.190 |
Why?
|
| Gene Expression Regulation | 1 | 2011 | 2061 | 0.190 |
Why?
|
| Enterocolitis | 1 | 2022 | 13 | 0.190 |
Why?
|
| Adenomatous Polyposis Coli Protein | 2 | 2019 | 42 | 0.190 |
Why?
|
| Steroids | 2 | 2020 | 174 | 0.180 |
Why?
|
| Opportunistic Infections | 1 | 2022 | 60 | 0.180 |
Why?
|
| ErbB Receptors | 3 | 2016 | 513 | 0.180 |
Why?
|
| Losartan | 2 | 2019 | 30 | 0.180 |
Why?
|
| Irritable Bowel Syndrome | 2 | 2020 | 46 | 0.180 |
Why?
|
| Induction Chemotherapy | 2 | 2019 | 151 | 0.180 |
Why?
|
| Cell Proliferation | 4 | 2021 | 1753 | 0.180 |
Why?
|
| Anastomosis, Surgical | 2 | 2022 | 283 | 0.180 |
Why?
|
| Chicago | 2 | 2018 | 1506 | 0.180 |
Why?
|
| HCT116 Cells | 3 | 2017 | 164 | 0.170 |
Why?
|
| Drug Resistance | 2 | 2019 | 237 | 0.170 |
Why?
|
| Calbindin 2 | 1 | 2021 | 5 | 0.170 |
Why?
|
| Receptors, Prostaglandin E, EP4 Subtype | 1 | 2021 | 5 | 0.170 |
Why?
|
| Cytomegalovirus Infections | 1 | 2022 | 155 | 0.170 |
Why?
|
| Cohort Studies | 4 | 2022 | 3110 | 0.170 |
Why?
|
| Th17 Cells | 2 | 2019 | 97 | 0.170 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2022 | 164 | 0.170 |
Why?
|
| Biomarkers | 4 | 2024 | 1930 | 0.170 |
Why?
|
| Liver Neoplasms | 1 | 2007 | 793 | 0.170 |
Why?
|
| Colonic Diseases | 1 | 2021 | 61 | 0.170 |
Why?
|
| Cellular Reprogramming | 1 | 2021 | 51 | 0.170 |
Why?
|
| Ostomy | 1 | 2020 | 15 | 0.160 |
Why?
|
| Endoscopy | 3 | 2021 | 374 | 0.160 |
Why?
|
| Wnt Signaling Pathway | 1 | 2021 | 103 | 0.160 |
Why?
|
| Biosimilar Pharmaceuticals | 1 | 2020 | 26 | 0.160 |
Why?
|
| United States | 7 | 2025 | 7768 | 0.160 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 3 | 2019 | 180 | 0.160 |
Why?
|
| Cytosine | 1 | 2020 | 135 | 0.160 |
Why?
|
| Stem Cells | 1 | 2022 | 394 | 0.160 |
Why?
|
| Animals | 13 | 2022 | 28891 | 0.150 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 122 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 18 | 0.150 |
Why?
|
| Drug Substitution | 1 | 2019 | 28 | 0.150 |
Why?
|
| Incidence | 2 | 2016 | 1715 | 0.150 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 1010 | 0.150 |
Why?
|
| Biomarkers, Tumor | 3 | 2022 | 1670 | 0.140 |
Why?
|
| Interleukin-8 | 2 | 2016 | 88 | 0.140 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2018 | 41 | 0.140 |
Why?
|
| Health Resources | 1 | 2019 | 82 | 0.140 |
Why?
|
| Prednisolone | 1 | 2018 | 37 | 0.140 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2020 | 308 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 7229 | 0.140 |
Why?
|
| Injections, Intravenous | 1 | 2018 | 238 | 0.140 |
Why?
|
| Cross-Sectional Studies | 2 | 2014 | 1876 | 0.140 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2021 | 350 | 0.140 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2018 | 102 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2019 | 134 | 0.130 |
Why?
|
| Histocytochemistry | 1 | 2017 | 132 | 0.130 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2018 | 311 | 0.130 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 2534 | 0.130 |
Why?
|
| Sensitivity and Specificity | 2 | 2018 | 2039 | 0.130 |
Why?
|
| ADAM17 Protein | 1 | 2016 | 9 | 0.130 |
Why?
|
| Chemokine CXCL2 | 1 | 2016 | 16 | 0.130 |
Why?
|
| Zinc | 1 | 2017 | 101 | 0.120 |
Why?
|
| Occludin | 1 | 2016 | 66 | 0.120 |
Why?
|
| Renin | 1 | 2016 | 67 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2016 | 49 | 0.120 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2016 | 70 | 0.120 |
Why?
|
| Genome, Human | 1 | 2020 | 824 | 0.120 |
Why?
|
| JC Virus | 1 | 2015 | 5 | 0.120 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 528 | 0.120 |
Why?
|
| Up-Regulation | 2 | 2020 | 740 | 0.120 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2015 | 11 | 0.120 |
Why?
|
| Natalizumab | 1 | 2015 | 21 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2022 | 2474 | 0.110 |
Why?
|
| Cadherins | 1 | 2016 | 179 | 0.110 |
Why?
|
| DNA | 1 | 2020 | 1333 | 0.110 |
Why?
|
| Surgical Wound Infection | 1 | 2017 | 237 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2020 | 1730 | 0.110 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2778 | 0.110 |
Why?
|
| Receptor Cross-Talk | 1 | 2014 | 33 | 0.110 |
Why?
|
| Sacroiliitis | 1 | 2014 | 3 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2016 | 481 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2019 | 441 | 0.110 |
Why?
|
| Spondylitis, Ankylosing | 1 | 2014 | 30 | 0.110 |
Why?
|
| Arthralgia | 1 | 2014 | 41 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 647 | 0.100 |
Why?
|
| Antibodies, Viral | 1 | 2015 | 348 | 0.100 |
Why?
|
| Healthcare Disparities | 1 | 2018 | 491 | 0.100 |
Why?
|
| Liver | 1 | 2018 | 1238 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2014 | 516 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2014 | 238 | 0.090 |
Why?
|
| DNA, Complementary | 1 | 2013 | 394 | 0.090 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2014 | 465 | 0.090 |
Why?
|
| Genetic Markers | 1 | 2013 | 479 | 0.090 |
Why?
|
| Adipokines | 1 | 2011 | 18 | 0.090 |
Why?
|
| Epithelial Cells | 4 | 2019 | 705 | 0.090 |
Why?
|
| Lectins | 1 | 2011 | 86 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2019 | 2480 | 0.090 |
Why?
|
| Mice, Inbred C57BL | 4 | 2021 | 3489 | 0.080 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 701 | 0.080 |
Why?
|
| Apoptosis | 4 | 2019 | 1756 | 0.080 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 157 | 0.080 |
Why?
|
| In Situ Hybridization | 1 | 2011 | 312 | 0.080 |
Why?
|
| Sentinel Surveillance | 1 | 2010 | 23 | 0.080 |
Why?
|
| Microbiota | 1 | 2016 | 426 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2016 | 2614 | 0.080 |
Why?
|
| Blotting, Western | 1 | 2011 | 796 | 0.080 |
Why?
|
| Infant | 1 | 2016 | 3363 | 0.080 |
Why?
|
| Child | 2 | 2022 | 7625 | 0.080 |
Why?
|
| Age Factors | 1 | 2014 | 1963 | 0.080 |
Why?
|
| Mice, Transgenic | 3 | 2021 | 1645 | 0.070 |
Why?
|
| Child, Preschool | 1 | 2016 | 3974 | 0.070 |
Why?
|
| Caco-2 Cells | 2 | 2019 | 125 | 0.070 |
Why?
|
| Treatment Failure | 2 | 2019 | 297 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 1828 | 0.070 |
Why?
|
| Postoperative Period | 2 | 2021 | 318 | 0.070 |
Why?
|
| Diet | 1 | 2011 | 460 | 0.070 |
Why?
|
| Cells, Cultured | 3 | 2021 | 2939 | 0.070 |
Why?
|
| Drug Administration Schedule | 2 | 2019 | 873 | 0.070 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2019 | 46 | 0.070 |
Why?
|
| Inpatients | 2 | 2021 | 347 | 0.070 |
Why?
|
| Propensity Score | 2 | 2018 | 180 | 0.060 |
Why?
|
| Transcriptional Activation | 2 | 2020 | 303 | 0.060 |
Why?
|
| Hepacivirus | 1 | 2007 | 137 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2006 | 81 | 0.060 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 813 | 0.060 |
Why?
|
| Rituximab | 1 | 2006 | 133 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 2777 | 0.060 |
Why?
|
| RNA, Messenger | 1 | 2011 | 2090 | 0.060 |
Why?
|
| Luminescence | 1 | 2024 | 20 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2019 | 1010 | 0.050 |
Why?
|
| Luciferases | 1 | 2024 | 130 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2880 | 0.050 |
Why?
|
| Genome-Wide Association Study | 2 | 2022 | 1765 | 0.050 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2022 | 2494 | 0.050 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2025 | 209 | 0.050 |
Why?
|
| Tuberculosis | 1 | 2024 | 125 | 0.050 |
Why?
|
| Pore Forming Cytotoxic Proteins | 1 | 2022 | 54 | 0.050 |
Why?
|
| Dextran Sulfate | 2 | 2013 | 70 | 0.050 |
Why?
|
| Immunologic Factors | 1 | 2023 | 179 | 0.050 |
Why?
|
| Cytomegalovirus | 1 | 2022 | 89 | 0.050 |
Why?
|
| Osteonectin | 1 | 2022 | 22 | 0.050 |
Why?
|
| Mice, Knockout | 2 | 2019 | 2161 | 0.050 |
Why?
|
| Neoplasms | 1 | 2017 | 3248 | 0.040 |
Why?
|
| Organoids | 1 | 2022 | 78 | 0.040 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2021 | 19 | 0.040 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2021 | 23 | 0.040 |
Why?
|
| Karyopherins | 1 | 2020 | 15 | 0.040 |
Why?
|
| Morphogenesis | 1 | 2022 | 211 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2021 | 80 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 109 | 0.040 |
Why?
|
| CpG Islands | 1 | 2020 | 169 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2022 | 930 | 0.040 |
Why?
|
| Cell Survival | 1 | 2022 | 1030 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2020 | 286 | 0.040 |
Why?
|
| Forkhead Transcription Factors | 1 | 2021 | 180 | 0.040 |
Why?
|
| DNA, Circular | 1 | 2019 | 12 | 0.040 |
Why?
|
| France | 1 | 2019 | 54 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2019 | 22 | 0.040 |
Why?
|
| Claudin-2 | 1 | 2019 | 10 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 40 | 0.040 |
Why?
|
| NF-kappa B | 2 | 2013 | 469 | 0.040 |
Why?
|
| STAT1 Transcription Factor | 1 | 2019 | 58 | 0.040 |
Why?
|
| Janus Kinase 2 | 1 | 2019 | 59 | 0.040 |
Why?
|
| Gene Frequency | 1 | 2021 | 703 | 0.040 |
Why?
|
| Multifactorial Inheritance | 1 | 2021 | 202 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2019 | 89 | 0.040 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2019 | 62 | 0.040 |
Why?
|
| Vitamins | 1 | 2019 | 86 | 0.040 |
Why?
|
| Histones | 1 | 2020 | 363 | 0.040 |
Why?
|
| Liver Function Tests | 1 | 2018 | 94 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2020 | 1083 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2019 | 547 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2019 | 1049 | 0.030 |
Why?
|
| Acute Disease | 1 | 2019 | 872 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 688 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 98 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 883 | 0.030 |
Why?
|
| Cytokines | 1 | 2021 | 871 | 0.030 |
Why?
|
| Medical Records | 1 | 2017 | 126 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2016 | 21 | 0.030 |
Why?
|
| Transforming Growth Factor alpha | 1 | 2016 | 50 | 0.030 |
Why?
|
| Hydralazine | 1 | 2016 | 21 | 0.030 |
Why?
|
| Fumarates | 1 | 2016 | 20 | 0.030 |
Why?
|
| Ambulatory Care | 1 | 2018 | 198 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2019 | 1157 | 0.030 |
Why?
|
| Spiro Compounds | 1 | 2016 | 30 | 0.030 |
Why?
|
| DNA-Binding Proteins | 1 | 2022 | 1267 | 0.030 |
Why?
|
| Amides | 1 | 2016 | 56 | 0.030 |
Why?
|
| Diet, Western | 1 | 2016 | 45 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 465 | 0.030 |
Why?
|
| Illinois | 1 | 2017 | 531 | 0.030 |
Why?
|
| Seroepidemiologic Studies | 1 | 2015 | 57 | 0.030 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2018 | 358 | 0.030 |
Why?
|
| RNA | 1 | 2019 | 605 | 0.030 |
Why?
|
| Ligands | 1 | 2016 | 478 | 0.030 |
Why?
|
| Prevalence | 1 | 2019 | 1349 | 0.030 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2016 | 259 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2017 | 713 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2019 | 611 | 0.030 |
Why?
|
| Azathioprine | 1 | 2015 | 125 | 0.030 |
Why?
|
| Snail Family Transcription Factors | 1 | 2014 | 48 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 1805 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2018 | 491 | 0.030 |
Why?
|
| Trinitrobenzenesulfonic Acid | 1 | 2013 | 16 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2019 | 847 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 3240 | 0.020 |
Why?
|
| Tight Junctions | 1 | 2013 | 153 | 0.020 |
Why?
|
| Chitinase-3-Like Protein 1 | 1 | 2011 | 9 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2014 | 369 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2013 | 301 | 0.020 |
Why?
|
| G1 Phase | 1 | 2011 | 66 | 0.020 |
Why?
|
| Azoxymethane | 1 | 2011 | 84 | 0.020 |
Why?
|
| Macrophages | 1 | 2014 | 623 | 0.020 |
Why?
|
| Cetuximab | 1 | 2011 | 119 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2018 | 2860 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2011 | 206 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 270 | 0.020 |
Why?
|
| Cell Movement | 1 | 2011 | 816 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2011 | 1973 | 0.020 |
Why?
|
| Mutation | 1 | 2019 | 4374 | 0.020 |
Why?
|
| Rats | 1 | 2011 | 4155 | 0.010 |
Why?
|